Houseplace influence on the avian utilization of pine monocultures, Savannah River Plant, South Carolina

The purpose of this study was to measure the avifaunal utilization of abandoned farm houseplaces and selected pine stand monocultures. A further consideration was the influence of houseplaces on the avian composition of adjacent pine stands. The study was conducted on the Energy Research and Development Administration\u27s Savannah River Plant, South Carolina, during the period April-July, 1976. The study area consisted of five study plots of nine hectares each. Forty-four species were recorded in the area during the study period. Fifteen species were breeding, and 29 were visitants. Importance value was utilized to determine that the pine warbler (IV = 125.6) and brown-headed nuthatch (120.1) were the two most important species in the managed pine habitat. The Carolina chickadee (114.3) and cardinal (106.5) were the two most important species in the houseplace habitat. These four species comprised 48.3 percent of all individuals recorded. Avian populations of houseplace-pine stand plots were compared to pine stands without houseplaces using the coefficient of community. The similarity of these two communities was .237 indicating dissimilar avian composition. Breeding bird diversity between the houseplace-pine stand plots and the pine stand without houseplace was significantly different (p\u3c.01). Total bird diversity (breeding and visitant) for the two habitats was also significantly different (p\u3c.05). Results indicate that houseplaces provided a habitat diversity which attracted bird species not occurring in the pine stands without houseplaces. This was true of breeding birds and visitants. Evaluation of the results suggests that management practices aimed at maintaining or increasing avian diversity in pine regions of the Savannah River Plant incorporate the houseplace concept

Issues in Zulu relativization

Zulu is a language of the Nguni group of the South-Eastern Zone of Bantu languages and is spoken by approximately 5 400 000 people. As far back as 1848, the Zulu language was investigated by a missionary of the American Board in Natal, James C. Bryant. In that year his ideas on the language were put on paper under the title, The Zulu Language, and this valuable contribution of some 13 pages was published in the following year in the Journal of the Oriental Society . Bryant's work heralded the beginning of a tradition of analysis in Zulu that was to capture the interest of a number of investigators over a period stretching up until the present day

Coronary Sinus Diverticulum and Accessory Pathway

A rare case of coronary sinus diverticulum is herein presented in a patient with classical Wolff-Parkinson-White syndrome undergoing catheter ablation of a posteroseptal accessory pathway. Only after a coronary venous angiogram was performed was the location of the accessory pathway identified and successfully ablated

Validation of Neural Network Predictions for the Outcome of Refractive Surgery for Myopia

Background: Refractive surgery (RS) for myopia has made a very big progress regarding its safety and predictability of the outcome. Still, a small percentage of operations require retreatment. Therefore, both legally and ethically, patients should be informed that sometimes a corrective RS may be required. We addressed this issue using Neural Networks (NN) in RS for myopia. This was a recently developed validation study of a NN.  Methods: We anonymously searched the Ophthalmica Institute of Ophthalmology and Microsurgery database for patients who underwent RS with PRK, LASEK, Epi-LASIK or LASIK between 2010 and 2018. We used a total of 13 factors related to RS. Data was divided into four sets of successful RS outcomes used for training the NN, successful RS outcomes used for testing the NN performance, RS outcomes that required retreatment used for training the NN and RS outcomes that required retreatment used for testing the NN performance. We created eight independent Learning Vector Quantization (LVQ) networks, each one responding to a specific query with 0 (for the retreat class) or 1 (for the correct class). The results of the 8 LVQs were then averaged so we could obtain a best estimate of the NN performance. Finally, a voting procedure was used to reach to a conclusion. Results: There was a statistically significant agreement (Cohen’s Kappa = 0.7658) between the predicted and the actual results regarding the need for retreatment. Our predictions had good sensitivity (0.8836) and specificity (0.9186). Conclusion: We validated our previously published results and confirmed our expectations for the NN we developed. Our results allow us to be optimistic about the future of NNs in predicting the outcome and, eventually, in planning RS

JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma

Chromosome 17q21-ter is commonly gained in neuroblastoma, but it is unclear which gene in the region is important for tumorigenesis. The JMJD6 gene at 17q21-ter activates gene transcription. Here we show that JMJD6 forms protein complexes with N-Myc and BRD4, and is important for E2F2, N-Myc and c-Myc transcription. Knocking down JMJD6 reduces neuroblastoma cell proliferation and survival in vitro and tumor progression in mice, and high levels of JMJD6 expression in human neuroblastoma tissues independently predict poor patient prognosis. In addition, JMJD6 gene is associated with transcriptional super-enhancers. Combination therapy with the CDK7/super-enhancer inhibitor THZ1 and the histone deacetylase inhibitor panobinostat synergistically reduces JMJD6, E2F2, N-Myc, c-Myc expression, induces apoptosis in vitro and leads to neuroblastoma tumor regression in mice, which are significantly reversed by forced JMJD6 over-expression. Our findings therefore identify JMJD6 as a neuroblastoma tumorigenesis factor, and the combination therapy as a treatment strategy

Cytochrome P450(cin) (CYP176A), isolation, expression, and characterization

Cytochromes P450 are members of a superfamily of hemoproteins involved in the oxidative metabolism of various physiologic and xenobiotic compounds in eukaryotes and prokaryotes. Studies on bacterial P450s, particularly those involved in monoterpene oxidation, have provided an integral contribution to our understanding of these proteins, away from the problems encountered with eukaryotic forms. We report here a novel cytochrome P450 (P450(cin), CYP176A1) purified from a strain of Citrobacter braakii that is capable of using cineole 1 as its sole source of carbon and energy. This enzyme has been purified to homogeneity and the amino acid sequences of three tryptic peptides determined. By using this information, a PCR-based cloning strategy was developed that allowed the isolation of a 4-kb DNA fragment containing the cytochrome P450(cin) gene (cinA). Sequencing revealed three open reading frames that were identified on the basis of sequence homology as a cytochrome P450, an NADPH-dependent flavodoxin/ferrodoxin reductase, and a flavodoxin. This arrangement suggests that P450(cin) may be the first isolated P450 to use a flavodoxin as its natural redox partner. Sequencing also identified the unprecedented substitution of a highly conserved, catalytically, important active site threonine with an asparagine residue. The P450 gene was subcloned and heterologously expressed in Escherichia coli at similar to2000 nmol/liter of original culture, and purification was achieved by standard protocols. Postulating the native E. coli flavodoxin/flavodoxin reductase system might mimic the natural redox partners of P450,in, it was expressed in E. coli in the presence of cineole 1. A product was formed in vivo that was tentatively identified by gas chromatography-mass spectrometry as 2-hydroxycineole 2. Examination of P450(cin) by UV-visible spectroscopy revealed typical spectra characteristic of P450s, a high affinity for cineole 1 (K-D = 0.7 mum), and a large spin state change of the heme iron associated with binding of cineole 1. These facts support the hypothesis that cineole 1 is the natural substrate for this enzyme and that P450(cin) catalyzes the initial monooxygenation of cineole 1 biodegradation. This constitutes the first characterization of an enzyme involved in this pathway

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes